Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation

Leukemia and Lymphoma

Volumn 49, Issue SUPPL. 1, 2008, Pages 59-66

  O'Connor, Owen A ^a   Czuczman, Myron S ^b  

^a NewYork Presbyterian Hospital   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Bortezomib; Immunomodulatory drugs; Lenolidamide; Non Hodgkin lymphoma; Proteasome inhibition

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GALIXIMAB; IMMUNOMODULATING AGENT; LENALIDOMIDE; PR 171; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; SALINOSPORAMIDE A; THALIDOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE PAIN; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; ERYTHEMA; FEVER; FOLLICULAR LYMPHOMA; HUMAN; LYMPHADENITIS; LYMPHOCYTE COUNT; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, NON-HODGKIN; PROTEASE INHIBITORS; PYRAZINES; THALIDOMIDE;

EID: 53249137871     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802365033     Document Type: Article

References (48)

1. Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T. Velankar, M. et al. (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell, 8, pp. 407-419.
2. Chauhan, D., Chao, T. H., Catley, L., Nicholson, B., Velankar, M. Hideshima, T. et al. (2005) In vitro and in vivo proteasome activity profiles of bortezomib and a novel proteasome inhibitor NPI-0052. Blood, 106, p. 3363 (abstract).
3. Miller, C. P., Ban, K., Ruiz, S. L., Neuteboom, S. T., Palladino, M. A. McConkey, D. et al. (2005) The novel, orally active proteasome inhibitor, NPI-0052, induces apoptosis in leukemia lymphoma cell lines and patient specimens. Blood, 106, p. 241 (abstract).
4. Suzuki, E., Jazirehi, A., Palladino, M. A. and Bonavida, B. (2005) Chemosensitization of drug and rituximab-resistant daudi B-NHL clones to drug-induced apoptosis by the proteasome inhibitor NPI-0052. Blood, 106, p. 1521 (abstract).
5. Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M. Ho, M. N. et al. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res, 67, pp. 6383-6391.
6. Pahler, J. C., Ruiz, S., Niemer, I., Calvert, L. R., Andreeff, M. Keating, M. et al. (2003) Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res, 9, pp. 4570-4577.
7. Chauhan, D., Catley, L., Velankar, M., Letai, A., Hideshima, T. Podar, K. et al. (2005) Requirement of caspase-8 versus caspase-9 during apoptosis in multiple myeloma cells induced by bortezomib or a novel proteasome inhibitor NPI-0052. Blood, 106, p. 3378 (abstract).
8. O'Connor, O. A., Moskowitz, C., Wright, J., MacGregor-Cortelli, B., Straus, D. Furst, D. et al. (2002) Phase II clinical experience with the proteasome inhibitor PS-341 in patients with indolent lymphomas. Blood, 100, p. 3063.
9. Belch, A., Kouroukis, T., Crump, M., Sehn, L., Gascoyne, R. Klasa, R. et al. (2004) Phase II trial of bortezomib in mantle cell lymphoma. Blood, 104, p. 608 (abstract).
10. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E. Hagemeister, F. et al. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 667-675.
11. Goy, A., Bernstein, S. H., Kahl, B. S., Epner, E., Leonard, J. P. Stadtmauer, E. A. et al. (2005) Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study. J Clin Oncol, 23, p. 6563. (abstract).
12. O'Connor, O. A., Wright, J., Moskowitz, C., Straus, D., Portlock, C. S. Hamlin, P. et al. (2005) Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: Results of a multicenter phase II experience. Ann Oncol, 16, p. 99. (abstract).
13. Strauss, S., Maharaj, L., Hoare, S., Trehu, E., Boral, A. Schenkein, D. et al. (2005) Bortezomib (Velcade) in patients with relapsed/refractory lymphoma: Potential correlation of TNF-alpha response and in vitro sensitivity with clinical activity. Ann Oncol, 16, p. 97. (abstract).
14. Dimopoulos, M. A., Anagnostopoulos, A., Kyrtsonis, M. C., Castritis, E., Bitsaktsis, A. and Pangalis, G. A. (2005) Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica, 90, pp. 1655-1658.
15. Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J. Boral, A. et al. (2006) Bortezomib in relapse or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study. J Clin Oncol, 24, p. 7512. (ASCO Meeting abstract).
16. Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J. de, V. S. et al. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol, 24, pp. 4867-4874.
17. Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A. Facon, T. et al. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med, 352, pp. 2487-2498.
18. NCCN (2007) NCCN Clinical Practice Guidelines in oncology: Non-Hodgkin's lymphomas (v3.2007).
19. Greco, F. A., Spigel, D. R., Barton, J. H., Farley, C., Schreeder, M. T. Hermann, R. C. et al. (2006) Weekly bortezomib in the treatment of patients (pts) with previously treated multiple myeloma: A phase II trial of the Minnie Pearl cancer research network. J Clin Oncol, 24, p. 7547. (ASCO Meeting abstract).
20. Gerecitano, J., Portlock, C. S., Noy, A., Hamlin, P., Moskowitz, C. Straus, D. et al. (2006) The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, inpatients with relapsed/refractory indolent B-cell lymphoproliferative disorders. Blood, 108, p. 2759. (abstract).
21. Perez-Galan, P., Roue, G., Villamor, N., Montserrat, E., Campo, E. and Colomer, D. (2006) The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 107, pp. 257-264.
22. Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D. Richardson, P. et al. (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 101, pp. 1530-1534.
23. Bartlett, J. B., Dredge, K. and Dalgleish, A. G. (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer, 4, pp. 314-322.
24. Kumar, S. and Rajkumar, S. V. (2006) Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer, 42, pp. 1612-1622.
25. Marriott, J. B., Dredge, K. and Dalgleish, A. G. (2003) Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents. Curr Drug Targets Immune Endocr Metab Disord, 3, pp. 181-186.
26. Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C. Davies, F. et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, pp. 3063-3067.
27. Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G. Tai, Y. T. et al. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, pp. 210-216.
28. Gupta, D., Treon, S. P., Shima, Y., Hideshima, T., Podar, K. Tai, Y. T. et al. (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 15, pp. 1950-1961.
29. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E. Tai, Y. T. et al. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, pp. 2943-2950.
30. Gandhi, A. K., Kang, J., Naziruddin, S., Parton, A., Schafer, P. H. and Stirling, D. I. (2006) Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res, 30, pp. 849-858.
31. Verhelle, D., Corral, L. G., Wong, K., Mueller, J. H., Moutouh-de, P. L. Jensen-Pergakes, K. et al. (2007) Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res, 67, pp. 746-755.
32. Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A. and Kaplan, G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med, 177, pp. 1675-1680.
33. Fujita, J., Mestre, J. R., Zeldis, J. B., Subbaramaiah, K. and Dannenberg, A. J. (2001) Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2. Clin Cancer Res, 7, pp. 3349-3355.
34. Dredge, K., Horsfall, R., Robinson, S. P., Zhang, L. H., Lu, L. Tang, Y. et al. (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res, 69, pp. 56-63.
35. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G. Hideshima, T. et al. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99, pp. 4525-4530.
36. Schafer, P. H., Gandhi, A. K., Loveland, M. A., Chen, R. S., Man, H. W. Schnetkamp, P. P. et al. (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther, 305, pp. 1222-1232.
37. Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H. Raje, N. et al. (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application. Br J Haematol, 128, pp. 192-203.
38. Corral, L. G., Haslett, P. A., Muller, G. W., Chen, R., Wong, L. M. Ocampo, C. J. et al. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol, 163, pp. 380-386.
39. Wu, L., Schafer, P., Muller, G., Stirling, D. and Bartlett, J. B. (2006) Lenalidomide strongly enhances natural killer (NK) cell mediated antibody-dependent cellular cytotoxicity (ADCC) of rituximab treated non-Hodgkin's lymphoma cell lines in vitro. Blood, 108, p. 3714. (abstract).
40. Kay, N. E. (2004) The angiogenic status of B-CLL B cells: Role of the VEGF receptors. Leuk Res, 28, pp. 221-222.
41. Mitsiades, C. S. and Mitsiades, N. (2004) CC-5013 (Celgene). Curr Opin Invest Drugs, 5, pp. 635-647.
42. Hernandez-Ilizaliturri, F. J., Jupudy, V., Ostberg, J., Oflazoglu, E., Huberman, A. Repasky, E. et al. (2003) Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res, 9, pp. 5866-5873.
43. Hernandez-Ilizaliturri, F. J., Reddy, N., Holkova, B., Ottman, E. and Czuczman, M. S. (2005) Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res, 11, pp. 5984-5992.
44. Reddy, N., Hernandez-Ilizaliturri, F. J., Deeb, G., Roth, M., Vaughn, M. Knight, J. et al. (2008) Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol, 140, pp. 36-45.
45. Suvas, S., Singh, V., Sahdev, S., Vohra, H. and Agrewala, J. N. (2002) Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem, 277, pp. 7766-7775.
46. Chanan-Khan, A., Miller, K. C., DiMceli, L., Padmanabhan, S., Lawrence, D. Bernstein, Z. P. et al. (2005) Results of phase II study of lenalidomide (L) (Revlimid) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood, 106, p. 447.
47. Witzig, T. E., Vose, J. M., Kaplan, H. P., Wolf, J. L., Pietronigro, D. Takeshita, K. et al. (2006) Early results from a phase II study of lenalidomide monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma. Blood, 108, p. 2482. (abstract).
48. Wiernik, P. H., Lossos, I., Tuscano, J., Justice, G., Vose, J. Pietronigro, D. et al. (2006) Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. Blood, 108, p. 531. (abstract).